PMID- 9268217
OWN - NLM
STAT- MEDLINE
DCOM- 19971001
LR  - 20190724
IS  - 0160-2446 (Print)
IS  - 0160-2446 (Linking)
VI  - 30
IP  - 1
DP  - 1997 Jul
TI  - Moderate alcohol feeding attenuates postinjury vascular cell proliferation in 
      rabbit angioplasty model.
PG  - 19-25
AB  - Our studies in the cholesterol-fed rabbit model indicate that moderate alcohol 
      consumption reduces the risk of restenosis by preventing low-density lipoprotein 
      (LDL) oxidation. Eighteen hypercholesterolemic rabbits underwent arterial injury 
      by Fogerty balloon endothelial denudation of iliac arteries. Two weeks later, 
      balloon angioplasty of atherogenic or atherosclerotic arterial segments was 
      performed. Nine rabbits (control) received water ad lib, whereas nine rabbits 
      (moderate alcohol treated) received an average of 2.5 ml alcohol per 500 ml water 
      daily, from the day of feeding hypercholesterolemic diet until they were killed, 
      10 weeks later. There was a 26% increase in lumen size of the moderate 
      alcohol-treated group compared with the control group. The percentage neointima 
      formation (NI) values of the moderate alcohol-treated and control groups were 77 
      +/- 2.1 and 61 +/- 1.9, respectively (p < 0.001). The lumen/neointima (L/NI) 
      ratio of the moderate alcohol-treated group was 0.71 +/- 0.07 compared with the 
      control group, 0.33 +/- 0.04 (p < 0.001). The number of foam cells in the 
      moderate alcohol-treated group was threefold less than the control group [i.e., 
      1.4 +/- 0.4 and 3.9 +/- 0.8, respectively (p = 0.005)]. The arterial lesion 
      malondialdehyde (MDA) values of the control and the moderate alcohol-treated 
      groups were 13.6 +/- 2.8 and 4.4 +/- 0.5 (p = 0.004), respectively. By 
      radioimmunoassay, the moderate alcohol-treated group had less macrophage 
      chemotactic protein-1 (MCP-1; 3,277 cpm/microg protein) and platelet-derived 
      growth factor (PDGF; 2,261 cpm/microg protein) compared with the controls (MCP-1, 
      4,529 cpm/microg protein; PDGF, 3,583 cpm/microg protein). Thus we conclude that 
      low concentrations of alcohol reduce neointimal formation, and the extent of 
      lipid oxidation, the number of foam cells in the neointimal area and may decrease 
      the expression of MCP-1 and PDGF by reducing LDL oxidation in an animal model of 
      postangioplasty restenosis.
FAU - Merritt, R
AU  - Merritt R
AD  - Department of Medicine, St. Louis University Health Science Center, Missouri 
      63110, U.S.A.
FAU - Guruge, B L
AU  - Guruge BL
FAU - Miller, D D
AU  - Miller DD
FAU - Chaitman, B R
AU  - Chaitman BR
FAU - Bora, P S
AU  - Bora PS
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - United States
TA  - J Cardiovasc Pharmacol
JT  - Journal of cardiovascular pharmacology
JID - 7902492
RN  - 0 (Chemokine CCL2)
RN  - 0 (Cholesterol, Dietary)
RN  - 0 (Cholesterol, HDL)
RN  - 0 (Lipoproteins, LDL)
RN  - 0 (Platelet-Derived Growth Factor)
RN  - 3K9958V90M (Ethanol)
RN  - 97C5T2UQ7J (Cholesterol)
SB  - IM
MH  - Angioplasty, Balloon/*adverse effects
MH  - Animals
MH  - Arteriosclerosis/etiology/metabolism/pathology/*prevention & control
MH  - Cell Division/drug effects
MH  - Chemokine CCL2/metabolism
MH  - Cholesterol/blood
MH  - Cholesterol, Dietary/administration & dosage
MH  - Cholesterol, HDL/blood
MH  - Ethanol/administration & dosage/*pharmacology
MH  - Iliac Artery/drug effects/injuries/metabolism/pathology
MH  - Lipid Peroxidation/drug effects
MH  - Lipoproteins, LDL/metabolism
MH  - Male
MH  - Muscle, Smooth, Vascular/*drug effects/injuries/metabolism/pathology
MH  - Platelet-Derived Growth Factor/metabolism
MH  - Rabbits
MH  - Recurrence
MH  - Tunica Intima/drug effects/pathology
EDAT- 1997/07/01 00:00
MHDA- 1997/07/01 00:01
CRDT- 1997/07/01 00:00
PHST- 1997/07/01 00:00 [pubmed]
PHST- 1997/07/01 00:01 [medline]
PHST- 1997/07/01 00:00 [entrez]
AID - 10.1097/00005344-199707000-00004 [doi]
PST - ppublish
SO  - J Cardiovasc Pharmacol. 1997 Jul;30(1):19-25. doi: 
      10.1097/00005344-199707000-00004.